Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
64
DMAC Quote, Financials, Valuation and Earnings
Last price:
$8.80
Seasonality move
:
25.24%
Day range:
$8.61 - $8.96
52-week range:
$3.19 - $9.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.86x
Volume:
240.8K
Avg. volume:
437.5K
1-year change:
63.5%
Market cap:
$457.2M
Revenue:
--
EPS (TTM):
-$0.72
Analysts' Opinion
-
Consensus RatingDiaMedica Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.50, DiaMedica Therapeutics, Inc. has an estimated upside of 76.54% from its current price of $8.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $8.78.
Fair Value
-
According to the consensus of 5 analysts, DiaMedica Therapeutics, Inc. has 76.54% upside to fair value with a price target of $15.50 per share.
DMAC vs. S&P 500
-
Over the past 5 trading days, DiaMedica Therapeutics, Inc. has overperformed the S&P 500 by 1.42% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
DiaMedica Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
DiaMedica Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter DiaMedica Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
DiaMedica Therapeutics, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter DiaMedica Therapeutics, Inc. reported earnings per share of -$0.17.
Enterprise value:
402.2M
EV / Invested capital:
7.75x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.41x
EV / Free cash flow:
-14.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$43K
Return On Assets:
-70.57%
Net Income Margin (TTM):
--
Return On Equity:
-79.25%
Return On Invested Capital:
-78.63%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$62K | -$36K | -$43K | -$10K | -$18K | |
| Operating Income | -$19.4M | -$24.1M | -$33.6M | -$6.9M | -$9M | |
| EBITDA | -$19.3M | -$24.1M | -$33.6M | -$6.9M | -$9M | |
| Diluted EPS | -$0.62 | -$0.55 | -$0.72 | -$0.15 | -$0.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $48.5M | $36.5M | $47.9M | $50.8M | $56.2M | |
| Total Assets | $48.7M | $37M | $58.1M | $52.5M | $57M | |
| Current Liabilities | $1.6M | $1.5M | $2.2M | $4.3M | $5.3M | |
| Total Liabilities | $1.6M | $2M | $2.5M | $4.6M | $5.4M | |
| Total Equity | $47M | $35.1M | $55.6M | $48M | $51.6M | |
| Total Debt | $8K | $427K | $342K | $277K | $167K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.4M | -$19.2M | -$27.7M | -$4.5M | -$6.6M | |
| Cash From Investing | -$20.2M | $9.7M | -$5.3M | -$5.5M | -$26.2M | |
| Cash From Financing | $37M | $11.3M | $32.2M | $159.9K | $32M | |
| Free Cash Flow | -$17.5M | -$19.2M | -$27.7M | -$4.5M | -$6.6M | |
DMAC
Sector
Market Cap
$457.2M
$28.5M
Price % of 52-Week High
95.13%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-9.12%
-1.33%
1-Year Price Total Return
63.5%
-20.32%
Beta (5-Year)
1.312
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.61
200-day SMA
Buy
Level
$5.35
Bollinger Bands (100)
Buy
Level
5.25 - 7.51
Chaikin Money Flow
Sell
Level
-4.5M
20-day SMA
Buy
Level
$7.42
Relative Strength Index (RSI14)
Buy
Level
64.48
ADX Line
Buy
Level
21.26
Williams %R
Sell
Level
-13.1195
50-day SMA
Buy
Level
$7.06
MACD (12, 26)
Buy
Level
0.54
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
13.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.6783)
Sell
CA Score
(Annual)
Level (-0.9626)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.401)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Stock Forecast FAQ
In the current month, DMAC has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DMAC average analyst price target in the past 3 months is $15.50.
-
Where Will DiaMedica Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that DiaMedica Therapeutics, Inc. share price will rise to $15.50 per share over the next 12 months.
-
What Do Analysts Say About DiaMedica Therapeutics, Inc.?
Analysts are divided on their view about DiaMedica Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DiaMedica Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is DiaMedica Therapeutics, Inc.'s Price Target?
The price target for DiaMedica Therapeutics, Inc. over the next 1-year time period is forecast to be $15.50 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DMAC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for DiaMedica Therapeutics, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DMAC?
You can purchase shares of DiaMedica Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DiaMedica Therapeutics, Inc. shares.
-
What Is The DiaMedica Therapeutics, Inc. Share Price Today?
DiaMedica Therapeutics, Inc. was last trading at $8.80 per share. This represents the most recent stock quote for DiaMedica Therapeutics, Inc.. Yesterday, DiaMedica Therapeutics, Inc. closed at $8.78 per share.
-
How To Buy DiaMedica Therapeutics, Inc. Stock Online?
In order to purchase DiaMedica Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DMAC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DMAC
Sector
P/E ratio
--
23.75x
PEG ratio
-0.41x
-0.01x
P/B ratio
8.86x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
DMAC
Sector
Revenue growth
--
4.85%
Earnings growth
-18.41%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.16
-$0.20
Profitability
DMAC
Sector
Profitability FY 2024
-$39K
$3.6M
Return on invested capital
-78.63%
-30.98%
Return on assets
-70.57%
-27.62%
Return on equity
-79.25%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
11
Balance Sheet
DMAC
Sector
Total cash
$55.3M
$27.2M
Short term investments
$41.1M
$25.7M
Total assets
$46.3M
$79.7M
Long term debt
$167K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
